The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients
Tóm tắt
To evaluate the feasibility of 18F-FDG PET/CT for initial assessment in high-grade bone sarcomas (BS) and soft tissue sarcomas (STS). During the years 2001–2010, 89 patients (30 BS, 59 STS) referred for further evaluation and surgical treatment of a high-grade BS or STS also had a PET/CT scan performed for staging preoperatively (n = 68) or within 1 month of surgery (n = 21). Metastatic lesions suggested on the PET/CT scan were confirmed or rejected by histological evaluation, by additional imaging or by follow-up. In 68 patients (28 BS, 40 STS) the relationship between the maximal standardized uptake value (SUVmax) of the primary tumour and survival was examined. The PET/CT scan suggested the presence of 13 metastatic lesions in BS patients (5 lymph node, 8 distant) and 21 metastatic lesions (6 lymph node, 15 distant) in STS patients. The calculated sensitivity (SE) and specificity (SP) were 95 % and 96 % for detection of distant metastases, and the predictive value (PV) of a positive or a negative test was 87 % and 98 %, respectively. SE and SP were 100 % and 90 % for detection of lymph node metastases, and the PV of a positive or a negative test was 27 % and 100 %, respectively. The 5-year survival was 81 % among patients with SUVmax below the median value (≤10), but was 33 % among those with SUVmax >10. FDG PET/CT for the initial assessment of patients with high-grade BS or STS was feasible with high SE and SP, but in those with lymph node metastases the PV of a positive test was low. The SUVmax of the primary tumour was a strong prognostic factor for survival.
Tài liệu tham khảo
Fletcher CDM, Unni KK, Mertens F, editors. WHO classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002.
Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchére D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914–26.
Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin Proc. 2007;82:1409–32.
Ducimetiére F, Lurkin A, Ranchére-Vince D, Decouvelaere AV, Péoc’h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6:e20294.
Ferrari E, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer. 2011;57:943–9.
Storm HH. Survival of adult patients with cancer of soft tissues or bone in Europe. EUROCARE Working Group. Eur J Cancer. 1998;34:2212–7.
Chow WA. Update on chondrosarcomas. Curr Opin Oncol. 2007;19:371–6.
Bernstain M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing’s sarcoma family of tumors: current management. Oncologist. 2006;11:505–19.
Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol. 2005;6:85–92.
Hogendoorn PC, Athanasou N, Bielack S, Alava ED, Tos AP, Ferrari S, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:204–13.
Casali PG, Blay JY. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:198–203.
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980;153:106–20.
Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.
Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Højgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging. 2005;32:1167–75.
Confidence interval calculator (last updated 1 February 2011). www.pedro.org.au/wp-content/uploads/CIcalculator.xls. Accessed 30 May 2012
Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft tissue sarcoma: preoperative staging with fluorodeoxyglucose PET/CT and conventional imaging. Radiology. 2007;245(3):839–47.
Kleis M, Daldrup-Link H, Matthay K, Goldsby R, Lu Y, Schuster T, et al. Diagnostic value of PET/CT for the staging and re staging of pediatric tumors. Eur J Nucl Med Mol Imaging. 2009;36:23–36.
Tateishi U, Hosono A, Makimoto A, Sakurada A, Terauchi T, Arai Y, et al. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas. J Pediatr Hematol Oncol. 2007;29(9):608–12.
Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, et al. Comparative study of FDG PET/CT and conventional imaging in staging of rhabdomyosarcoma. Ann Nucl Med. 2009;23(2):155–61.
Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25(34):5435–41.
Jeffree GM, Price CH, Sissons HA. The metastatic pattern of osteosarcoma. Br J Cancer. 1975;32:87–107.
Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voue PA, Gadner H, Craft AW. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18:3108–14.
Wahl R. Principles of cancer imaging with fluorodeoxyglucose. In: Wahl RL, editor. Principles and practice of positron emission tomography. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 100–10.
Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg. 2004;127:1087–92.
Györke T, Zajic T, Lange A, Schäfer O, Moser E, Makó E, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun. 2006;27(1):17–24.
Charest M, Hickeson M, Lisbona R, Novales-Diaz J-A, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging. 2009;36:1944–51.
Cook GJ. Skeletal and soft tissue. In: Wahl RL, editor. Principles and practice of positron emission tomography. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 246–51.
Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction for outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging. 2004;31:189–95.
Eary JF, O’Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med. 2002;29:1149–54.
Schwarzbach MHM, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative (18-F)fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005;241:286–94.
Scheutze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad III EU, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339–48.
Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20.